The drug development process is often stalled by the "blind spots" between dosing and traditional histopathology. Durametrix was founded to close this gap. The TITAN™ platform and Noceravide™ provide a peer-reviewed framework for transforming preclinical development. By integrating longitudinal imaging, systemic chemistry, and gold-standard pathology, we provide a transparent and highly sensitive lens into candidate/asset behavior. Our methodology has been independently validated and is supported by peer-reviewed research published in some of the world's most respected oncology and nuclear medicine journals. The following publications represent a decade of research demonstrating how greater visibility into asset behavior can help reduce uncertainty and risk throughout preclinical development—because when you have the ability to see the total truth, you reduce the risk of clinical failure.